AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28162931 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 205
Study 26241254 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 10 mg administered 30-60 minutes before surgical abortion.
Number of subjects: 124
Study 26241254 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 30-60 minutes before surgical abortion.
Number of subjects: 124
Study 23882930 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir for 200 days
Number of subjects: 100
Study 23882930 — intervention group
Group type: COMPARATOR
Intervention: Valganciclovir for 110 days
Number of subjects: 100
Study 20803856 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml*h(‐1) ropivacaine 0.2% (study group, n = 21)
Number of subjects: 42
Study 20803856 — intervention group
Group type: COMPARATOR
Intervention: 5 ml*h(‐1) saline (control group, n = 21)
Number of subjects: 42
Study 18763292 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal stage nutrition support
Number of subjects: 43
Study 18763292 — intervention group
Group type: COMPARATOR
Intervention: Total parental nutrition (TPN) in combination with operation
Number of subjects: 43
Study 16377319 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytolong brush (CB)
Number of subjects: 102
Study 16377319 — intervention group
Group type: COMPARATOR
Intervention: Geenen brush (GB)
Number of subjects: 102
Study 12571499 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtalar distraction bone‐block arthrodesis with tricortical bone graft
Number of subjects: 424
Study 12571499 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 424
Study 12571499 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation
Number of subjects: 424
Study 12571499 — intervention group
Group type: COMPARATOR
Intervention: Böhler angle <0 degrees
Number of subjects: 424
Study 12571499 — intervention group
Group type: COMPARATOR
Intervention: Sanders-type IV fractures
Number of subjects: 424
Study 12571499 — intervention group
Group type: COMPARATOR
Intervention: Worker's Compensation Board status
Number of subjects: 424
Study 11086664 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg
Number of subjects: 12
Study 11086664 — intervention group
Group type: EXPERIMENTAL
Intervention: granisetron 2 mg
Number of subjects: 12
Study 11086664 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 8828422 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hormone replacement therapy (first 6 months)
Number of subjects: 23
Study 8828422 — intervention group
Group type: COMPARATOR
Intervention: Suspension of hormone replacement therapy (first 6 months)
Number of subjects: 23
Study 8828422 — intervention group
Group type: EXPERIMENTAL
Intervention: Resumption of hormone replacement therapy (after 6 months)
Number of subjects: 23
Study 8828422 — intervention group
Group type: COMPARATOR
Intervention: Suspension of hormone replacement therapy (after 6 months)
Number of subjects: 23
Study 1448310 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole oral gel
Number of subjects: 757
Study 1448310 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 757
Study 30689736 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 therapy (nivolumab)
Number of subjects: 51
Study 30689736 — intervention group
Group type: EXPERIMENTAL
Intervention: Major pathologic response on biopsy (MPRbx)
Number of subjects: 51
Study 30689736 — intervention group
Group type: COMPARATOR
Intervention: Stable disease
Number of subjects: 51
Study 28926525 — intervention group
Group type: EXPERIMENTAL
Intervention: Be Resilient to Breast Cancer (BRBC)
Number of subjects: 226
Study 28926525 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 226
Study 26960919 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful extubation
Number of subjects: 174
Study 26960919 — intervention group
Group type: EXPERIMENTAL
Intervention: Extubation failure
Number of subjects: 174
Study 26960919 — intervention group
Group type: EXPERIMENTAL
Intervention: Extubation failure (adjusted for allocated treatment)
Number of subjects: 174
Study 25359435 — intervention group
Group type: EXPERIMENTAL
Intervention: SleepPro 1™ (SP1)
Number of subjects: 90
Study 25359435 — intervention group
Group type: EXPERIMENTAL
Intervention: SleepPro 2™ (SP2)
Number of subjects: 90
Study 25359435 — intervention group
Group type: EXPERIMENTAL
Intervention: Bespoke MAD (bMAD)
Number of subjects: 90
Study 25359435 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 90
Study 22735801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Triamcinolone Acetonide (4 mg)
Number of subjects: 55
Study 22735801 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal Bevacizumab (1.25 mg)
Number of subjects: 55
Study 19534840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane Database of Systematic Reviews (CDSR)
Number of subjects: 0
Study 18510694 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (LcS)
Number of subjects: 20
Study 18510694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16430011 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-etch adhesive (Adper Scotchbond MultiPurpose) with incremental insertion technique
Number of subjects: 48
Study 16430011 — intervention group
Group type: COMPARATOR
Intervention: Self-etching adhesive (iBond) with bulk insertion technique
Number of subjects: 48
Study 12614089 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing physicians with alcohol screening results and recommendations for their patients at a visit.
Number of subjects: 312
Study 12614089 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who saw resident physicians in the intervention group.
Number of subjects: 312
Study 10583283 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloving
Number of subjects: 80
Study 10583283 — intervention group
Group type: COMPARATOR
Intervention: Single gloving
Number of subjects: 80
Study 10583283 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep surgical procedures
Number of subjects: 80
Study 10583283 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial surgical procedures
Number of subjects: 80
Study 8904621 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg daily simvastatin
Number of subjects: 621
Study 8904621 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg daily simvastatin
Number of subjects: 621
Study 8904621 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 621
Study 1809526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine prophylaxis
Number of subjects: 55
Study 1809526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 6400110 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 0
Study 6400110 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0
Study 6400110 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 0
Study 6400110 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 0
Study 6400110 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0
Study 6400110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30507677 — intervention group
Group type: EXPERIMENTAL
Intervention: SstO2 monitoring during surgery
Number of subjects: 50
Study 30507677 — intervention group
Group type: COMPARATOR
Intervention: SstO2 monitoring
Number of subjects: 50
Study 28622463 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib (100 mg twice daily or 30, 75, 150, 200, or 300 mg once daily)
Number of subjects: 127
Study 28622463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 26565785 — intervention group
Group type: EXPERIMENTAL
Intervention: RLO+ (interactive videos plus standard clinical service)
Number of subjects: 203
Study 26565785 — intervention group
Group type: COMPARATOR
Intervention: RLO- (standard clinical service only)
Number of subjects: 203
Study 25121980 — intervention group
Group type: EXPERIMENTAL
Intervention: Parotid gland massage for 1 minute
Number of subjects: 44
Study 25121980 — intervention group
Group type: EXPERIMENTAL
Intervention: Parotid gland massage for 2 minutes
Number of subjects: 44
Study 25121980 — intervention group
Group type: COMPARATOR
Intervention: Control (1-minute interval without massage)
Number of subjects: 44
Study 25121980 — intervention group
Group type: COMPARATOR
Intervention: Control (2-minute interval without massage)
Number of subjects: 44
Study 21875223 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (6 mg)
Number of subjects: 20
Study 21875223 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 20
Study 19786825 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine iontophoresis at the upper site on the forearm
Number of subjects: 16
Study 19786825 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine iontophoresis at the lower site on the forearm
Number of subjects: 16
Study 19786825 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated iontophoresis at the same site
Number of subjects: 16
Study 19786825 — intervention group
Group type: EXPERIMENTAL
Intervention: Data expressed as percentage of shared variance after heating
Number of subjects: 16
Study 17532416 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐E Perimount (stented bioprosthesis)
Number of subjects: 161
Study 17532416 — intervention group
Group type: EXPERIMENTAL
Intervention: Prima Plus (stentless bioprosthesis)
Number of subjects: 161
Study 15189262 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-oriented practical (POP) course
Number of subjects: 228
Study 15189262 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal bedside teaching (PBT) course
Number of subjects: 228
Study 15189262 — intervention group
Group type: COMPARATOR
Intervention: Standard practical course
Number of subjects: 228
Study 15189262 — intervention group
Group type: EXPERIMENTAL
Intervention: POP and PBT courses
Number of subjects: 228
Study 11172123 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Burch colposuspension
Number of subjects: 74
Study 11172123 — intervention group
Group type: COMPARATOR
Intervention: Classic Burch colposuspension
Number of subjects: 74
Study 10338904 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol aerosol 42 micrograms twice daily
Number of subjects: 538
Study 10338904 — intervention group
Group type: COMPARATOR
Intervention: Placebo (as‐needed albuterol)
Number of subjects: 538
Study 8275438 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg gabexate mesilate, intravenously twice a day for 5 days after TAE
Number of subjects: 34
Study 8275438 — intervention group
Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 34
Study 8275438 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg gabexate mesilate
Number of subjects: 34
Study 2498383 — intervention group
Group type: COMPARATOR
Intervention: 4-hour continuous intravenous infusion of GH (180-micrograms bolus dose, then 3 micrograms/min)
Number of subjects: 8
Study 2498383 — intervention group
Group type: COMPARATOR
Intervention: 6-hour continuous intravenous infusion of GH (180-micrograms bolus dose, then 3 micrograms/min)
Number of subjects: 8
Study 30664549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamaldehyde (TRPA1 sensitizer)
Number of subjects: 16
Study 30664549 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (TRPV1 sensitizer)
Number of subjects: 16
Study 30664549 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol (TRPM8 sensitizer)
Number of subjects: 16
Study 29121724 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (n=104)
Number of subjects: 414
Study 29121724 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (n=160)
Number of subjects: 414
Study 29121724 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (n=150)
Number of subjects: 414
Study 29121724 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CHA2DS2-VASc score
Number of subjects: 414
Study 26502785 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention program (1-year systematic follow-up)
Number of subjects: 0
Study 26502785 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 0
Study 23246672 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% O2
Number of subjects: 13
Study 23246672 — intervention group
Group type: COMPARATOR
Intervention: Compressed Air (CA)
Number of subjects: 13
Study 21592510 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal resuscitation (n = 343)
Number of subjects: 2006
Study 21592510 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-mask ventilation (n = 372)
Number of subjects: 2006
Study 21592510 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation (n = 1205)
Number of subjects: 2006
Study 21592510 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation (n = 86)
Number of subjects: 2006
Study 21592510 — intervention group
Group type: EXPERIMENTAL
Intervention: All levels of resuscitation
Number of subjects: 2006
Study 21592510 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted rates of bronchopulmonary dysplasia and severe retinopathy
Number of subjects: 2006
Study 17852721 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought suppression paradigm with autobiographical experiences as target thoughts
Number of subjects: 0
Study 17067136 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium 40 mg x kg(‐1) for 5 min at 6.5 min before induction
Number of subjects: 55
Study 17067136 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.02 mg x kg(‐1) at 1.5 min before induction
Number of subjects: 55
Study 17067136 — intervention group
Group type: COMPARATOR
Intervention: Saline 1-2 ml at 1.5 min before induction
Number of subjects: 55
Study 12667899 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (10%, 30%, and 50% N(2)O in O(2))
Number of subjects: 13
Study 12667899 — intervention group
Group type: COMPARATOR
Intervention: 100% O(2) (placebo)
Number of subjects: 13
Study 9862836 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal bowel sonography (T)
Number of subjects: 213
Study 8551420 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced osmolarity ORS (245 mmol/L sodium and glucose)
Number of subjects: 190
Study 8551420 — intervention group
Group type: COMPARATOR
Intervention: Standard WHO ORS (311 mmol/L)
Number of subjects: 190
Study 1880751 — intervention group
Group type: EXPERIMENTAL
Intervention: Coded consonants at F=500 Hz
Number of subjects: 24
Study 1880751 — intervention group
Group type: EXPERIMENTAL
Intervention: Coded consonants at F=300 Hz
Number of subjects: 24
Study 1880751 — intervention group
Group type: COMPARATOR
Intervention: Lowpass filtered speech at F=500 Hz
Number of subjects: 24
Study 1880751 — intervention group
Group type: COMPARATOR
Intervention: Lowpass filtered speech at F=300 Hz
Number of subjects: 24
Study 1880751 — intervention group
Group type: EXPERIMENTAL
Intervention: Coded vowels at F=500 Hz
Number of subjects: 24
Study 1880751 — intervention group
Group type: EXPERIMENTAL
Intervention: Coded vowels at F=300 Hz
Number of subjects: 24
Study 1880751 — intervention group
Group type: EXPERIMENTAL
Intervention: Coded consonants in CV syllables at F=500 Hz
Number of subjects: 24
Study 1880751 — intervention group
Group type: EXPERIMENTAL
Intervention: Coded vowels in CV syllables at F=500 Hz
Number of subjects: 24
Study 6882881 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent acetylsalicylic acid (ASA)
Number of subjects: 8
Study 6882881 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental ASA formulation
Number of subjects: 8
Study 6882881 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered ASA
Number of subjects: 8
Study 6882881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6882881 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent ASA
Number of subjects: 8
Study 6882881 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental ASA
Number of subjects: 8
Study 30132262 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850-1700 mg)
Number of subjects: 97
Study 30132262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 29980120 — intervention group
Group type: EXPERIMENTAL
Intervention: Building Spiritual Strength (BSS)
Number of subjects: 138
Study 29980120 — intervention group
Group type: COMPARATOR
Intervention: Present Centered Group Therapy (PCGT)
Number of subjects: 138
Study 28471773 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine premedication
Number of subjects: 41
Study 28471773 — intervention group
Group type: COMPARATOR
Intervention: No atropine premedication
Number of subjects: 41
Study 26595894 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually oriented monetary reward incentives
Number of subjects: 0
Study 26595894 — intervention group
Group type: EXPERIMENTAL
Intervention: Purely altruistic monetary reward incentives
Number of subjects: 0
Study 26595894 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid of competitive and cooperative monetary reward incentives
Number of subjects: 0
Study 26595894 — intervention group
Group type: COMPARATOR
Intervention: No incentive control condition
Number of subjects: 0
Study 26595894 — intervention group
Group type: EXPERIMENTAL
Intervention: All incentives (individually oriented, altruistic, competitive/cooperative)
Number of subjects: 0
Study 26595894 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent cognitive testing battery
Number of subjects: 0
Study 23320440 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-examination-style questioning
Number of subjects: 185
Study 23320440 — intervention group
Group type: COMPARATOR
Intervention: Direct examination questions
Number of subjects: 185
Study 21603629 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate 2 mg/kg/day
Number of subjects: 143
Study 21603629 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate 4 mg/kg/day
Number of subjects: 143
Study 21603629 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate 6 mg/kg/day
Number of subjects: 143
Study 19000552 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 25 mg pactimibe
Number of subjects: 24
Study 19000552 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of 100 mg pactimibe for 21 days in CYP2D6 PMs
Number of subjects: 24
Study 16797395 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 32
Study 16797395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12717144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 45
Study 12717144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 12717144 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 45
Study 11187921 — intervention group
Group type: EXPERIMENTAL
Intervention: L81‐10 protocol (1981‐1984)
Number of subjects: 1438
Study 11187921 — intervention group
Group type: EXPERIMENTAL
Intervention: L84‐11 protocol (1984‐1989)
Number of subjects: 1438
Study 11187921 — intervention group
Group type: EXPERIMENTAL
Intervention: L89‐12 protocol (1989‐1992)
Number of subjects: 1438
Study 11187921 — intervention group
Group type: EXPERIMENTAL
Intervention: L92‐13 protocol (1992‐1995)
Number of subjects: 1438
Study 11187921 — intervention group
Group type: COMPARATOR
Intervention: CNS relapse rates for L81‐10, L84‐11, L89‐12, L92‐13 protocols
Number of subjects: 1438
Study 11187921 — intervention group
Group type: EXPERIMENTAL
Intervention: NCI risk criteria for B‐precursor ALL
Number of subjects: 1438
Study 11187921 — intervention group
Group type: EXPERIMENTAL
Intervention: NCI risk criteria for T‐ALL
Number of subjects: 1438
Study 11187921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial irradiation
Number of subjects: 1438
Study 9332112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Magnesium sulfate (0.2 ml/kg of 50% MgSO4 as intravenous infusion over 35 minutes)
Number of subjects: 47
Study 9332112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Magnesium sulfate
Number of subjects: 47
Study 9332112 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline infusion in the same dose and at the same rate)
Number of subjects: 47
Study 8441894 — intervention group
Group type: EXPERIMENTAL
Intervention: Lozenges
Number of subjects: 18
Study 8441894 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 18
Study 8441894 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 18
Study 3741825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine (1.5 mg kg‐1)
Number of subjects: 0
Study 3741825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29424007 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 12
Study 29424007 — intervention group
Group type: COMPARATOR
Intervention: Placebo-IMT
Number of subjects: 12
Study 29424007 — intervention group
Group type: COMPARATOR
Intervention: Thoracic Load Carriage (LC)
Number of subjects: 12
Study 26553486 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg day(-1)
Number of subjects: 50
Study 26553486 — intervention group
Group type: COMPARATOR
Intervention: Continuation of standard insulin therapy
Number of subjects: 50
Study 23753256 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular self-weighing intervention (two telephone calls, offer of free weighing scales, encouragement to weigh weekly)
Number of subjects: 3768
Study 23753256 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 3768
Study 23753256 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular self-weighing intervention
Number of subjects: 3768
Study 23318127 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational booklet (IB)
Number of subjects: 191
Study 23318127 — intervention group
Group type: EXPERIMENTAL
Intervention: IB + didactic discussions (DD)
Number of subjects: 191
Study 23318127 — intervention group
Group type: EXPERIMENTAL
Intervention: IB + imaginal and direct exposure desensitization (ET)
Number of subjects: 191
Study 23318127 — intervention group
Group type: COMPARATOR
Intervention: IB
Number of subjects: 191